Kexing Biopharm Co., Ltd. (SHA:688136)

China · Delayed Price · Currency is CNY

18.43

+0.62 (3.48%)

Aug 4, 2026, 3:00 PM CST

Kexing Biopharm Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,461	1,534	1,407	1,259	1,316	1,285
Revenue Growth	4.37%	9.03%	11.75%	-4.32%	2.39%	5.32%
Gross Profit	894.26	969.71	962.73	888.72	991.21	1,020
Operating Income	46.3	88.08	98.52	-240.71	-125.34	42.21
Net Income	112.05	155.57	31.48	-190.29	-90.3	96.46
Earnings Per Share	0.57	0.79	0.16	-0.96	-0.45	0.49
EPS Growth	149.27%	393.75%	-	-	-	-47.31%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	1,168
Export	366.29
Total	1,534

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	628.04	650.43	554.56	568.8	785.38	877.62
Total Debt	1,410	1,397	1,221	1,116	1,039	601.27
Net Cash (Debt)	-782.12	-746.33	-666.22	-547.26	-253.16	276.35
Net Cash Growth	-	-	-	-	-	-64.88%
Net Cash Per Share	-3.96	-3.79	-3.39	-2.76	-1.26	1.40

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	67.5	86.03	106.67	-87.14	-85.89	94.01
Capital Expenditures	-88.54	-83.63	-93.99	-191.2	-399.17	-371.98
Free Cash Flow	-21.04	2.4	12.68	-278.34	-485.06	-277.97
Free Cash Flow Growth	-	-81.05%	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	61.21%	63.21%	68.43%	70.59%	75.33%	79.36%
Operating Margin	3.17%	5.74%	7.00%	-19.12%	-9.53%	3.28%
Pretax Margin	7.40%	10.80%	4.04%	-20.66%	-10.57%	7.44%
Profit Margin	7.67%	10.14%	2.24%	-15.11%	-6.86%	7.51%
FCF Margin	-1.44%	0.16%	0.90%	-22.11%	-36.86%	-21.63%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.250	0.250	0.080	-	-	0.100
Dividend Per Share Growth	212.50%	212.50%	-	-	-	25.00%
Dividend Yield	1.40%	0.80%	0.37%	-	-	0.36%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	31.40	40.33	137.32	-	-	58.23
Forward PE	28.73	38.04	41.58	-	-	-
P/FCF Ratio	-	2611.79	340.98	-	-	-
PS Ratio	2.41	4.09	3.07	3.20	3.24	4.37